Press release: update on fda priority review of dupixent for the treatment of copd patients with type 2 inflammation

Update on fda priority review of dupixent for the treatment of copd patients with type 2 inflammation paris and tarrytown, ny may 31, 2024. the us food and drug administration (fda) has extended by three months the target action date of its priority review of the supplemental biologics license application (sbla) for dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (copd).
REGN Ratings Summary
REGN Quant Ranking